Chemours Sees Unusually High Options Volume (NYSE:CC)

The Chemours Company (NYSE:CC) saw some unusual options trading activity on Wednesday. Traders bought 21,465 call options on the company. This is an increase of 633% compared to the typical daily volume of 2,930 call options.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CC shares. The Goldman Sachs Group reissued a “neutral” rating and set a $16.00 target price on shares of Chemours in a research note on Friday, October 9th. Morgan Stanley set a $18.00 target price on shares of Chemours in a report on Monday, August 10th. JPMorgan Chase & Co. cut their price target on shares of Chemours from $15.00 to $14.00 and set a “neutral” rating on the stock in a research report on Monday. Zacks Research downgraded Chemours from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 4th. Finally, Mizuho lowered Chemours from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $18.00 to $15.00 in a research report on Wednesday, October 14th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $17.36.

Institutional Investors Weigh In On Chemours

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. bought a new position in shares of Chemours during the 2nd quarter worth about $34,000. Allworth Financial LP acquired a new stake in shares of Chemours in the 2nd quarter valued at about $51,000. State of Wyoming acquired a new stake in shares of Chemours in the 2nd quarter valued at about $67,000. Sterling Capital Management LLC increased its position in Chemours by 839.3% in the 3rd quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after buying an additional 4,532 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in Chemours by 15.1% in the 3rd quarter. Parallel Advisors LLC now owns 5,926 shares of the specialty chemicals company’s stock valued at $80,000 after buying an additional 776 shares in the last quarter. 76.26% of the stock is owned by institutional investors.

Top Chemours Stories

These are some of the CC stories that stood out recently:

• Neutral Sentiment: Investors bought 21,465 Chemours call options on Wednesday, about 633% above the average volume of 2,930. This indicates unusually active options trading, but does not establish a clear direction for the stock. No article link was provided.
• Negative Sentiment: Multiple law firms reminded investors that December 7, 2026 is the deadline to seek lead-plaintiff status in a securities class action covering purchases from February 20 to August 4, 2026. The complaint alleges Chemours misrepresented demand for its Opteon refrigerants, including that strong 2025 sales masked an overfilled distribution channel and weaker underlying demand. These are allegations, not proven findings; the litigation could add uncertainty and potential costs. Article: CC Shareholder Alert
• Negative Sentiment: JPMorgan issued a pessimistic forecast for Chemours shares, adding to bearish sentiment. The supplied article information does not specify its price target or rationale. Article: JPMorgan Chase Issues Pessimistic Forecast for Chemours

Chemours Price Performance

Shares of CC opened at $13.73 on Thursday. Chemours has a 52-week low of $10.44 and a 52-week high of $28.67. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81. The business’s 50 day moving average price is $13.84 and its two-hundred day moving average price is $18.18. The firm has a market cap of $2.07 billion, a PE ratio of -13.47 and a beta of 1.47.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. Chemours’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.40 earnings per share. On average, equities analysts anticipate that Chemours will post 0.82 EPS for the current year.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be paid a dividend of $0.0875 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 annualized dividend and a yield of 2.5%. Chemours’s dividend payout ratio is currently -34.31%.

About Chemours

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.